Introduction {#Sec1}
============

Spontaneous subarachnoid hemorrhage (SAH) is one of the leading causes of neurologic morbidity and mortality, accounting for 27% of all stroke-related years of potential life lost before age 65 \[[@CR1]\]. SAH is associated with early brain injury, which is the primary cause of mortality in SAH patients and may be associated with the pathogenesis of cerebral vasospasm \[[@CR2]\]. Cerebral vasospasm is a known complication of SAH and another important cause of morbidity and mortality in SAH patients who survive aneurysm treatment \[[@CR3]\]. How early brain injury and cerebral vasospasm ultimately affect long-term SAH outcome in human subjects remain incompletely understood \[[@CR4]\], and there are few clinical molecular biomarkers for vasospasm and SAH outcome.

There is growing evidence that inflammation plays a key role in early brain injury and cerebral vasospasm \[[@CR2], [@CR5], [@CR6]\]. Elevation of leukocyte adhesion molecules and cytokines in cerebrospinal fluid (CSF) and serum are associated with changes in cerebral blood flow in SAH \[[@CR7], [@CR8]\]. Multiple animal and cross-sectional human studies have reported association between leukocytosis and the development of vasospasm or ischemia \[[@CR9]--[@CR11]\] and poor outcome \[[@CR12]--[@CR15]\] following SAH. The mechanism via which inflammation causes narrowing of cerebral arteries and brain injury is incompletely understood. Inflammatory cells such as leukocytes are a major source of MMPs after brain injury \[[@CR16]\]. MMP-9, in particular, may mediate early brain injury in SAH by causing neuronal apoptosis through disruption of neuron--extracellular matrix interaction \[[@CR17], [@CR18]\]. MMPs are also implicated in the disruption of blood--brain barrier (BBB) integrity, progression of cerebral edema, and worsening cerebral ischemic injury \[[@CR19]\], all of which may affect SAH clinical outcome. Furthermore, MMPs 2 and 9 can cleave big endothelin-1 (ET-1) into strongly vasoactive segments which further promote neutrophilic MMP release, creating a positive feedback loop that potentially mediates cerebral vasospasm \[[@CR20]--[@CR22]\]. MMP-9 therefore may mediate a poor SAH outcome via different and divergent pathogenic mechanisms and may be the link between inflammation and the genesis of "spasmogens" such as ET-1 in cerebral vasospasm following SAH. We hypothesize inflammation marked by leukocyte and neutrophil elevation in SAH is associated with MMP-9 elevation in blood and CSF, leading to vasospasm and worse SAH clinical outcome, and that peripheral leukocyte and neutrophil counts and blood and CSF MMP-9 may be useful biomarkers for vasospasm and outcome following SAH.

Methods {#Sec2}
=======

Subject Selection {#Sec3}
-----------------

Fifty five consecutive SAH patients within 96 h of spontaneous SAH were prospectively enrolled, and their blood and available CSF were sampled on post-SAH days 0--1, 2--3, 4--5, 6--8, and 10--14. CSF samples were acquired only from patients who had an external ventricular drain (EVD) placed for clinical indications. Patients with traumatic SAH, pregnancy, end-stage renal or hepatic disease, intracranial malignancies, or infectious meningitis were excluded. We selected a subcohort of subjects with both blood and CSF samples available for MMP-9 analysis (*N* = 35). All subjects were consented in accordance with institutional review board approved protocols.

Daily peripheral leukocyte and neutrophil count is extracted from subjects' medical records. Per clinical protocol, all SAH patients underwent daily complete blood count measurement using automatic flow cytometry (ADVIA 120, Siemens) by CLIO-certified clinical laboratory. For subjects who had more than one measurement on a single day, the highest measurement was recorded.

Blood samples for MMP-9 analysis were collected in heparin-coated tubes and immediately centrifuged at 3,900 rpm for 15 min, aliquotted, and then stored frozen at −80°C until analysis. CSF samples were collected under sterile conditions over 30 min from the anti-reflux burette in the EVD system. Upon collection, all samples were immediately centrifuged (3,900 rpm, 15 min at room temperature) and separated from cellular debris, aliquoted, and stored frozen at −80°C.

Total MMP-9 (active plus pro-MMP-9; R&D Systems, Minneapolis, MN) were measured using solid-phase ELISA by blinded investigators. All assays were run in duplicates using internal controls for each batch. Gel zymography was performed to assess MMP-9 activity and isoforms via previously described methods \[[@CR23]\].

Angiographic vasospasm was defined as \>50% reduction in diameter of any vessel on angiography on post-SAH days 6--8. Per institutional protocol, all SAH patients underwent digital subtraction cerebral angiography (DSCA) upon initial presentation and then again on post-SAH days 6--8 for evaluation of angiographic vasospasm. Severity of vasospasm was determined by comparing subsequent to baseline DSCA. The total number of vessel segments with vasospastic changes did not affect the grading of vasospasm. When multiple vessels were involved, subjects were classified based on the most severely affected vessel. Subjects who had several subsequent DSCAs were classified according to the most severe vasospasm seen among all DSCA.

Long-term functional outcome at 3-month post-SAH were prospectively assessed using modified Rankin score (mRS) via telephone interview. A standardized questionnaire was used to perform mRS scoring to reduce inter-rater variability. A poor outcome was defined as mRS \> 2.

Statistical Analysis {#Sec4}
--------------------

Continuous variables were compared using two-tailed Student's *t*-test or Wilcoxon rank sum test depending on data normality. Depending on data normality, Pearson or Spearman correlation was used to measure strength of association between continuous variables. Categorical variables were compared using Chi-square test. We used longitudinal regression analysis to model data with repeated measurements. All statistical analyses were performed using JMP 8.0 and SAS 9.2.

Results {#Sec5}
=======

Baseline Characteristics {#Sec6}
------------------------

Subject characteristics of the entire SAH cohort (*n* = 55) are summarized in Table [1](#Tab1){ref-type="table"}. Mean age, gender distribution, aneurysm locations, and incidences of vasospasm and poor outcome are comparable between the large SAH cohorts and the subset of subjects selected for MMP-9 analysis. Of the overall cohort, 49% presented with Hunt and Hess (HH) grade of 3 and above, whereas 60% of the MMP-9 subcohort presented with HH grade of 3 and above. The large majority of subjects have Fisher grade 3 SAH.Table 1Baseline characteristics of study cohortCharacteristics(N = 55)Age (mean years)53 (+/− 16)Female Gender (%)31 (56%)Hunt and Hess Grade 17 (13%) 221 (38%) 313 (24%) 49 (16%) 55 (9%)Fisher Grade 13 (5%) 211 (20%) 338 (69%) 43 (5%)Aneurysm Location Acom21 (38%) Pcom11 (20%) Angio Negative10 (18%) ICA3 (5%) PICA4 (7%) MCA3 (5%) Basilar1 (2%) ACA2 (4%)Angiographic Vasospasm22 (60%)3-month Outcome mRS \> 2 (bad)15 (28%) mRS ≤ 2 (good)39 (72%)6-month Outcome mRS \> 2 (bad)10 (20%) mRS ≤ 2 (good)41 (80%)

Elevated Blood Leukocyte and Neutrophil Counts are Associated with Vasospasm {#Sec7}
----------------------------------------------------------------------------

Subjects who developed angiographic vasospasm have higher leukocyte counts throughout post-SAH days 0--14 (*p* = 0.0003; Fig. [1](#Fig1){ref-type="fig"}). Individually, elevated peripheral leukocyte counts on post-SAH days 2 (*p* = 0.037), 3 (*p* = 0.046), 4 (*p* = 0.028), 5 (*p* = 0.025), 6 (*p* = 0.036), 7 (*p* = 0.0018), 8 (*p* = 0.0097), 9 (*p* = 0.0007), 10 (*p* = 0.0003), and 11 (*p* = 0.019) are associated with angiographic vasospasm. After adjustment for potential confounders including HH grade, age, and modality of SAH surgical treatment, elevated leukocyte counts throughout post-SAH days 0--14 remain independently associated with vasospasm (*p* = 0.0003).Fig. 1Peripheral white blood cell count is elevated in SAH subjects with angiographic vasospasm (VSP+; *n* = 22) compared with those without Vasospasm (VSP-; *n* = 33) during post-SAH days 0--14 (*p* = 0.0003). *\** indicates between-group difference on that specific post-SAH day is significant at a level of *p* \< 0.05

We also examined a specific subset of leukocytes --- neutrophils. Subjects who developed angiographic vasospasm have higher neutrophil counts throughout post-SAH days 0--14 (*p* = 0.0027; Fig. [2](#Fig2){ref-type="fig"}). Individually, elevated peripheral neutrophil counts on post-SAH days 0--1 (*p* = 0.018) and 6--8 (*p* = 0.0005) are associated with the development of angiographic vasospasm. After adjustment for potential confounders including HH grade, age, and modality of SAH surgical treatment, elevated neutrophil counts throughout post-SAH days 0--14 remained independently associated with vasospasm (*p* = 0.0002).Fig. 2Peripheral neutrophil count is elevated in SAH subjects with angiographic vasospasm (VSP+; *n* = 15) compared with those without vasospasm (VSP-; *n* = 23) during post-SAH days 0--14 (*p* = 0.0027). *\** indicates between-group difference on that specific post-SAH day is significant at a level of *p* \< 0.05

Elevated Neutrophil Count, Blood, and CSF MMP-9 are Associated with Poor 3-month SAH Outcome {#Sec8}
--------------------------------------------------------------------------------------------

Persistent blood neutrophil elevation throughout post-SAH days 0--14 is associated with poor 3-month SAH outcome (mRS \> 2; *p* = 0.018). Individually, elevated neutrophil count on post-SAH days 2--3 is associated with poor 3-month SAH outcome (*p* = 0.018; Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Peripheral neutrophil count is elevated during post-SAH days 0--14 in SAH subjects with poor (mRS \> 2; *n* = 12) 3-month outcome compared with those with good outcome (mRS ≤ 2; *n* = 25; *p* = 0.018). *\** indicates between-group difference on that specific post-SAH day is significant at a level of *p* \< 0.05

Persistent blood MMP-9 elevation throughout post-SAH days 0--14 showed a trend towards association with 3-month SAH outcome in a longitudinal regression model (*p* = 0.09). Specifically, elevated blood MMP-9 on post-SAH days 4--5 is associated with poor 3-month SAH outcome (*p* = 0.045; Fig. [4a](#Fig4){ref-type="fig"}).Fig. 4**a** Elevation of blood MMP-9 levels during post-SAH days 0--14 in SAH patients showed a trend of association with poor (mRS \> 2; *n* = 10) 3-month outcome versus good (mRS ≤ 2; *n* = 21) outcome (*p* = 0.09). **b** Elevation of CSF MMP-9 levels during post-SAH days 0--14 in SAH patients is associated with poor (mRS \> 2; *n* = 9) 3-month outcome versus good (mRS ≤ 2; *n* = 22; *p* = 0.0078). *\** indicates between-group difference on that specific post-SAH day is significant at a level of *p* \< 0.05)

MMP-9 is detectable in CSF at levels approximately 200-fold lower than that in blood. Zymogram confirmed that the MMP-9 present in the CSF is enzymatically active \[[@CR24]\], suggesting that it could functionally participate in the events triggered by SAH. Persistent elevation of CSF MMP-9 throughout post-SAH days 0--14 is associated with poor 3-month SAH outcome (*p* = 0.0078). Specifically, elevated CSF MMP-9 on post-SAH days 2--3 (*p* = 0.05) is associated with poor 3-month outcome (Fig. [4b](#Fig4){ref-type="fig"}).

Neutrophil Counts, Blood MMP-9, and CSF MMP-9 Correlations {#Sec9}
----------------------------------------------------------

In blood, neutrophil counts correlate with MMP-9 levels on post-SAH days 6--8 (*R* = 0.39; *p* = 0.055, Fig. [5a](#Fig5){ref-type="fig"}) and post-SAH days 10--14 (*R* = 0.79; *p* \< 0.0001, Fig. [5b](#Fig5){ref-type="fig"}). CSF MMP-9 correlates with blood MMP-9 on post-SAH days 4--5 (*R* = 0.72; *p* = 0.0002; Fig. [6](#Fig6){ref-type="fig"}). However, neither CSF (*p* = 0.32) nor blood MMP-9 (*p* = 0.42) were associated with angiographic vasospasm on statistical analysis (Fig. [7](#Fig7){ref-type="fig"}).Fig. 5Peripheral neutrophil counts correlate with blood MMP-9 levels **a** on post-SAH days 6--8 (*n* = 24; R = 0.39; *p* = 0.055) and **b** on post-SAH days 10--14 (*n* = 23; R = 0.79; *p* \< 0.0001)Fig. 6Blood MMP-9 correlates with CSF MMP9 on post-SAH days 4--5 (*n* = 22; *R* = 0.72; *p* = 0.0002)Fig. 7**a** Blood MMP-9 levels during post-SAH days 0--14 in SAH patients showed no association with presence (VSP+; *n* = 17) or absence of angiographic vasospasm (VSP-; *n* = 16; *p* = 0.42). **b** CSF MMP-9 levels during post-SAH days 0--14 in SAH patients showed no association with presence (VSP+; *n* = 17) or absence of angiographic vasospasm (VSP-; *n* = 15; *p* = 0.32)

Discussion {#Sec10}
==========

We found that early elevation of blood neutrophil count is associated with both cerebral vasospasm and poor 3-month clinical outcome after SAH, and both blood and CSF MMP-9 are associated with poor 3-month SAH clinical outcome but not with vasospasm. Early blood neutrophil count is associated with blood MMP-9 levels, suggesting that neutrophils may be an important source of blood MMP-9. Similarly, early blood MMP-9 elevation is associated with CSF MMP-9 elevation while blood MMP-9 levels are 200-fold higher than CSF MMP-9 levels, suggesting that blood MMP-9 may be an important source of CSF MMP-9 early in SAH.

Recent studies suggest MMPs may participate in the pathogenesis of cerebral vasospasm and early brain injury in multiple pathways. Activation of MMP-9 is associated with endothelial apoptosis, which plays an important role in cerebral ischemia after SAH \[[@CR25]\]. Furthermore, there is growing evidence supporting the important role of initial global ischemia in brain injury following SAH \[[@CR25]\]. MMPs are known to play important and different roles in acute ischemic brain injuries as well as in brain recovery from such injuries. Elevation of MMPs is associated with worse clinical outcome in acute peri-stroke phase while subacute MMP elevation promotes remodeling and recovery following ischemic injury \[[@CR26]\]. In concordance with these studies, we showed for the first time that early elevation of MMP-9 in CSF is associated with poor 3-month clinical outcome in human SAH subjects. Although we are unable to establish the source of CSF MMP-9 in this clinical study, our data suggest that MMP-9 likely plays an important role in early brain injury following SAH.

We also found a positive correlation between blood and CSF MMP-9 levels early in SAH course. Given their relative concentrations, it is conceivable that this positive correlation may represent blood MMP-9 leaking across the BBB into CSF. Whether blood and CSF MMP-9 play a direct pathogenic role in early brain injury or act as a surrogate for poor outcome mediated by degree of BBB disruption will need to be determined by more mechanistic in vitro studies. In our data, while MMP-9 in blood and CSF are associated with poor SAH outcome, they are not associated with angiographic vasospasm, suggesting that MMP-9 may lead to brain injury independent of vasospasm. These results support the growing hypothesis that there may be divergent pathophysiologic pathways leading to angiographic vasospasm and poor outcome in SAH \[[@CR27], [@CR28]\].

We also demonstrated, for the first time in humans, that elevation of peripheral neutrophil count is associated with both vasospasm and poor outcome in SAH. Prior clinical studies have established that blood leukocyte elevation at single time points are associated with cerebral vasospasm \[[@CR9], [@CR14]\], which we replicated in our study. However, none of these studies specifically examined neutrophils. Data from our study support results from animal studies demonstrating that reduced neutrophil activity is associated with less brain injury and better outcome in SAH \[[@CR29], [@CR30]\]. The correlation between early neutrophil elevation and blood MMP-9 elevation raise the possibility that neutrophils may mediate poor SAH outcome partly via MMP-9 release.

Our study has several caveats, the most important one being that this is an observational association study. While we carefully studied a prospective and well-phenotyped SAH cohort with longitudinal temporal data and measured MMP-9 in CSF as well as in blood, the overall sample size of this study is modest. With a small sample size, we have no power to meaningfully adjust for all confounders or to perform subset analysis. Given the modest sample size, we limited the risk of multiple comparisons by focusing on a single molecular marker --- MMP-9, a major product of neutrophils, in two compartments (blood and ventricular CSF). However, we recognize that SAH-related early brain injury is likely associated with changes in multiple interacting molecular pathways. Our data support MMP-9 as a potentially important mediator of poor SAH outcome, but we cannot comment on the specific pathophysiologic mechanism connecting MMP-9 and brain injury. For example, other important MMPs, in particular, the other gelatinase --- MMP-2, is also known to mediate important neuroinflammatory responses \[[@CR31], [@CR32]\] and chronic vascular inflammatory processes such as vascular cognitive impairment \[[@CR33]\]. In this exploratory study, we chose to focus on the acute inflammatory cascade involving the neutrophil --- MMP-9 axis --- because neutrophils are major sources of MMP-9 but not of MMP-2 \[[@CR34]\]. We acknowledge that MMP-2 may very well play a role in SAH-related cerebral injury and will examine MMP-2 in the future.

Clinically, due to patient safety considerations, we were only able to sample SAH subjects' blood at four time points between post-SAH days 0--14, and sample CSF only from EVD systems. This limits our ability to measure and correlate blood and CSF leukocyte and neutrophil counts reliably to examine the time course and degree of inflammation within the CSF compartment and its contribution to MMP-9 release in SAH. Moreover, we can only collect CSF samples from subjects who had EVD placement and CSF drainage for a clinical indication due to ethical considerations. This subset of subjects with both CSF and blood samples available were chosen for MMP-9 analysis. This may bias the selection of subjects for CSF biomarker study to those with clinical symptoms of hydrocephalus and those with higher HH grade, and thereby limit the generalizability of our results. In summary, while results from this initial study suggest that early peripheral inflammatory response and MMP-9 may be an important predictor of SAH clinical outcome, larger prospective studies, studies of other molecular mediators of SAH outcome, and in-depth bench studies are needed to understand and validate these findings.
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